Biochips Market, By Product (DNA Chip, Protein Chip, Lab-on-a-chip, and Others), By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Agriculture, and Others), By End-User (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostics Centers, Academic & Research Institutes, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Trends, Analysis and Forecast till 2034

Biochips Market was valued at US$ 10.5 billion in 2024 and is projected to grow at a CAGR of 14.8% to reach US$ 41.8 billion by 2034.

The complete fundamental functional unit that has capability to perform many biochemical tasks simultaneously is known as a biochip. The biochip is a miniature laboratory with a microarray that is arranged on a solid substrate having capability of performing multi biochemical tasks and thus allowing higher throughput of speed and volume. The adaptable applications of biochips are considered as a vital advancement in medical technology. Biochips are largely used for research in drug discovery and development, proteomics, genomics and molecular diagnostics.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Increasing application of biochips in the medical sector for cancer treatment, as biochips can detect cancer even before the development of symptoms, and diagnose it, which is the major factors driving the global biochips market growth. For instance, according to World Health Organization, in September 2018, with an estimated 9.6 million deaths in 2018, cancer has become the second leading cause for death worldwide.

 Additionally, it can easily detect virulent diseases such as small pox, anthrax and plague due to which it has a wide application in the healthcare sector and hence flourishing the target market. For instance, according to World Health Organization, in October 2017, plague is termed as severe disease with a fatality ratio of 30%-60% for bubonic type and 100% for pneumonic type when left untreated.

Furthermore, factors such as computerization of biochemical processes through the use of biochips, readiness of molecular information, and application of biochips for gene and protein identification are set to drive the global biochips market. Moreover, advancement in the technology in the biochips like microfluidics, DNA microarray, etc. is expected to drive the growth of the biochips market globally.

However, lack of proper knowledge about biochip technology is a major restraint to the global biochips market which is dropping the demand for biochip products. Further, variable cost of the adaption of the biochips also affects the target market adversely. Favorable economic reforms and surging mergers and acquisitions among major biochips companies are the leading driving forces for the global biochips market in the forecast period.

The biochips market report segments the market on the basis of product, application, end-user, and region.

On the basis of Product Type, the biochips market is segmented into DNA Chip, Protein Chip, Lab-on-a-chip, and Others. On the basis of Application, the target market is segmented into Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Agriculture, and Others. Based on End User the market is segmented into Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostics Centers, Academic & Research Institutes, and Others.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

For detailed understanding of market dynamics, the biochips market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the global market. North America market leads the biochips market in terms of revenue contribution as compared to that of markets in other regions. This is due to presence of government initiatives, well-developed healthcare infrastructure and significant number of ongoing research activities in the region. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue owing to the developing healthcare infrastructure, increasing adoption for biochips over conventional bulky instruments.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Biochips Market report based on Product, Application, End-user and region:

Biochips Market, By Product:

• DNA Chip
• Protein Chip
• Lab-on-a-chip
• Others

Biochips Market, By Application:

• Drug Discovery & Development
• Disease Diagnostics
• Genomics
• Proteomics
• Agriculture
• Others

Biochips Market, By End-user:

• Biotechnology & Pharmaceutical Companies
• Hospitals & Diagnostics Centers
• Academic & Research Institutes
• Others

Biochips Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Some of the prominent players operating in the biochips market include CDI laboratories, ThermoFisher Scientific, Affymetrix Inc., Illumina Inc., GE Healthcare Ltd., InDevR Inc., Agilent Technologies Inc., Fluidigm Corporation and Cepheid Inc., Randox Laboratories Ltd

Technological advancements in the product as well as strategic partnerships are some trends witnessed in the global biochips market. For instance, in July 2018, Agilent Technologies Inc. announced that it has completed the procurement of the business assets of ULTRA Scientific, Inc. which is a leading provider of chemical standards and certified reference materials. Further, in May 2017, CDI Labs expands HuProt which is the highest content human proteome microarray in the world in which over 1000 new recombinant proteins will be added.

• In June 2023, ACROBiosystems, through ACRO Certify and under its Aneuro brand, announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, the two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization.
• In November 2023, ASU students break new ground with axoniverse’s innovative biochip technology aims to improve computing efficiency with neurons, could be released as early as next year. This student company is redefining the boundaries between biology and technology by developing a first-of-its-kind biochip, Axomini, slated for release in 2024.

• ThermoFisher Scientific*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• CDI laboratories
• Affymetrix Inc.
• Illumina Inc.
• GE Healthcare Ltd.
• InDevR Inc.
• Agilent Technologies Inc.
• Fluidigm Corporation
• Cepheid Inc.
• Randox Laboratories Ltd

“*” marked represents similar segmentation in other categories in the respective section.